{
  "abstract": "Background/Objectives: Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) is a validated surrogate endpoint in HER2-positive and triple-negative breast cancer. Most work on blood-count-derived inflammatory indices has examined a single pretreatment value rather than change during treatment. We tested whether an early reduction in the pan-immune-inflammation value (PIV) predicts pCR. Methods: We studied 272 patients with HER2-positive or triple-negative stage II–III breast cancer treated at one centre: a discovery cohort treated in 2018–2021 (n = 191) and a temporally independent validation cohort treated in 2022–2023 (n = 81). Early ΔPIV was the proportional change between the baseline complete blood count and the count before the second or third cycle. The 30% reduction threshold was fixed before the analysis for clinical interpretability. Reporting followed STROBE and TRIPOD. Results: pCR occurred in 157 patients (57.7%). The median early ΔPIV was −0.44 in patients with pCR and −0.11 in those without (p < 0.001). The area under the curve was 0.80 (95% CI 0.73–0.86) in the discovery cohort and 0.84 (0.75–0.93) in validation. pCR was reached by 78.6% of patients with a ≥30% early reduction versus 37.6% without it in the discovery cohort, and by 77.8% versus 27.8% in the validation cohort. In the primary three-variable model, the adjusted odds ratio was 6.45 (2.90–14.32; p < 0.001) in the discovery cohort and 27.85 (3.93–197.36; p < 0.001) in the validation cohort. Adding early PIV reduction to clinicopathologic factors raised the area under the curve from 0.69 to 0.80 (difference 0.111, 95% CI 0.047–0.175; p < 0.001). Conclusions: Early PIV reduction is associated with pCR and adds information beyond established factors. At 69% sensitivity and 73% specificity it is a candidate adjunct rather than a decision rule, and prospective multicentre validation is required.",
  "abstract_shown": true,
  "affiliations": [
    "Department of General Surgery, Istanbul Medipol University, 34810 Istanbul, Türkiye"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 5,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Oguzhan Hakan Topgul",
      "orcid": "0000-0002-6292-890X"
    },
    {
      "affs": [
        0
      ],
      "name": "Perya Abbasoglu"
    },
    {
      "affs": [
        0
      ],
      "name": "Mahmut Zenciroglu"
    },
    {
      "affs": [
        0
      ],
      "name": "Caglar Kazim Pekuz"
    },
    {
      "affs": [
        0
      ],
      "name": "Pelin Basim",
      "orcid": "0000-0002-9452-9276"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/f8mrwsnvy17e9.bib",
  "cited_by": 0,
  "doi": "10.3390/jcm15218748",
  "fulltext_url": null,
  "id": "f8mrwsnvy17e9",
  "issns": [
    "2077-0383"
  ],
  "landing_url": "https://www.mdpi.com/2077-0383/15/21/8748",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [],
  "openalex": null,
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-09",
  "publisher": "MDPI AG",
  "ris": "https://research.draconitic.com/paper/f8mrwsnvy17e9.ris",
  "sources": [
    {
      "first_seen": "2026-11-10T00:21:41Z",
      "native_id": "10.3390/jcm15218748",
      "source": "crossref",
      "url": "https://www.mdpi.com/2077-0383/15/21/8748"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "journal-openalex:F27",
      "subfield": "general"
    }
  ],
  "title": "Early Change in the Pan-Immune-Inflammation Value During Neoadjuvant Chemotherapy Is Associated with Pathological Complete Response in HER2-Positive and Triple-Negative Breast Cancer: A Single-Centre Study with Temporal Validation",
  "title_text": "Early Change in the Pan-Immune-Inflammation Value During Neoadjuvant Chemotherapy Is Associated with Pathological Complete Response in HER2-Positive and Triple-Negative Breast Cancer: A Single-Centre Study with Temporal Validation",
  "type": "peer-reviewed",
  "updated_at": "2026-11-10T00:21:41Z",
  "url": "https://research.draconitic.com/paper/f8mrwsnvy17e9",
  "venue": "Journal of Clinical Medicine",
  "versions": []
}